These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
780 related articles for article (PubMed ID: 27122162)
1. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia. Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162 [TBL] [Abstract][Full Text] [Related]
2. C/EBPβ mediates tumour-induced ubiquitin ligase atrogin1/MAFbx upregulation and muscle wasting. Zhang G; Jin B; Li YP EMBO J; 2011 Aug; 30(20):4323-35. PubMed ID: 21847090 [TBL] [Abstract][Full Text] [Related]
3. Cryptotanshinone prevents muscle wasting in CT26-induced cancer cachexia through inhibiting STAT3 signaling pathway. Chen L; Yang Q; Zhang H; Wan L; Xin B; Cao Y; Zhang J; Guo C J Ethnopharmacol; 2020 Oct; 260():113066. PubMed ID: 32505837 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia. Silva KA; Dong J; Dong Y; Dong Y; Schor N; Tweardy DJ; Zhang L; Mitch WE J Biol Chem; 2015 Apr; 290(17):11177-87. PubMed ID: 25787076 [TBL] [Abstract][Full Text] [Related]
5. A standardized herbal combination of Astragalus membranaceus and Paeonia japonica, protects against muscle atrophy in a C26 colon cancer cachexia mouse model. Lee SB; Lee JS; Moon SO; Lee HD; Yoon YS; Son CG J Ethnopharmacol; 2021 Mar; 267():113470. PubMed ID: 33068652 [TBL] [Abstract][Full Text] [Related]
6. Cancer-Induced Muscle Wasting Requires p38β MAPK Activation of p300. Sin TK; Zhang G; Zhang Z; Zhu JZ; Zuo Y; Frost JA; Li M; Li YP Cancer Res; 2021 Feb; 81(4):885-897. PubMed ID: 33355181 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy. Reed SA; Sandesara PB; Senf SM; Judge AR FASEB J; 2012 Mar; 26(3):987-1000. PubMed ID: 22102632 [TBL] [Abstract][Full Text] [Related]
8. Matrine improves skeletal muscle atrophy by inhibiting E3 ubiquitin ligases and activating the Akt/mTOR/FoxO3α signaling pathway in C2C12 myotubes and mice. Chen L; Chen L; Wan L; Huo Y; Huang J; Li J; Lu J; Xin B; Yang Q; Guo C Oncol Rep; 2019 Aug; 42(2):479-494. PubMed ID: 31233199 [TBL] [Abstract][Full Text] [Related]
9. Expression of CCAAT/Enhancer Binding Protein Beta in Muscle Satellite Cells Inhibits Myogenesis in Cancer Cachexia. Marchildon F; Lamarche É; Lala-Tabbert N; St-Louis C; Wiper-Bergeron N PLoS One; 2015; 10(12):e0145583. PubMed ID: 26709824 [TBL] [Abstract][Full Text] [Related]
10. C/EBPβ promotes the expression of atrophy-inducing factors by tumours and is a central regulator of cancer cachexia. AlSudais H; Rajgara R; Saleh A; Wiper-Bergeron N J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):743-757. PubMed ID: 35014202 [TBL] [Abstract][Full Text] [Related]
11. Signaling mechanism of tumor cell-induced up-regulation of E3 ubiquitin ligase UBR2. Zhang G; Lin RK; Kwon YT; Li YP FASEB J; 2013 Jul; 27(7):2893-901. PubMed ID: 23568773 [TBL] [Abstract][Full Text] [Related]
12. Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia. Tseng YC; Kulp SK; Lai IL; Hsu EC; He WA; Frankhouser DE; Yan PS; Mo X; Bloomston M; Lesinski GB; Marcucci G; Guttridge DC; Bekaii-Saab T; Chen CS J Natl Cancer Inst; 2015 Dec; 107(12):djv274. PubMed ID: 26464423 [TBL] [Abstract][Full Text] [Related]
13. p300 Mediates Muscle Wasting in Lewis Lung Carcinoma. Sin TK; Zhu JZ; Zhang G; Li YP Cancer Res; 2019 Apr; 79(7):1331-1342. PubMed ID: 30705122 [TBL] [Abstract][Full Text] [Related]
14. Epigallocatechin-3-gallate effectively attenuates skeletal muscle atrophy caused by cancer cachexia. Wang H; Lai YJ; Chan YL; Li TL; Wu CJ Cancer Lett; 2011 Jun; 305(1):40-9. PubMed ID: 21397390 [TBL] [Abstract][Full Text] [Related]
15. Mountain ginseng inhibits skeletal muscle atrophy by decreasing muscle RING finger protein-1 and atrogin1 through forkhead box O3 in L6 myotubes. Seok YM; Yoo JM; Nam Y; Kim J; Kim JS; Son JH; Kim HJ J Ethnopharmacol; 2021 Apr; 270():113557. PubMed ID: 33161026 [TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor 4 mediates Lewis lung carcinoma-induced muscle wasting via coordinate activation of protein degradation pathways. Zhang G; Liu Z; Ding H; Miao H; Garcia JM; Li YP Sci Rep; 2017 May; 7(1):2273. PubMed ID: 28536426 [TBL] [Abstract][Full Text] [Related]
17. Luteolin reduces cancer‑induced skeletal and cardiac muscle atrophy in a Lewis lung cancer mouse model. Chen T; Li B; Xu Y; Meng S; Wang Y; Jiang Y Oncol Rep; 2018 Aug; 40(2):1129-1137. PubMed ID: 29845270 [TBL] [Abstract][Full Text] [Related]
18. Suppression of atrogin-1 and MuRF1 prevents dexamethasone-induced atrophy of cultured myotubes. Castillero E; Alamdari N; Lecker SH; Hasselgren PO Metabolism; 2013 Oct; 62(10):1495-502. PubMed ID: 23866982 [TBL] [Abstract][Full Text] [Related]
19. Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study. Yuan L; Han J; Meng Q; Xi Q; Zhuang Q; Jiang Y; Han Y; Zhang B; Fang J; Wu G Oncol Rep; 2015 May; 33(5):2261-8. PubMed ID: 25760630 [TBL] [Abstract][Full Text] [Related]
20. IL-17A contributes to skeletal muscle atrophy in lung cancer-induced cachexia via JAK2/STAT3 pathway. Ying L; Yao Y; Lv H; Lu G; Zhang Q; Yang Y; Zhou J Am J Physiol Cell Physiol; 2022 May; 322(5):C814-C824. PubMed ID: 35319902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]